New 12,000-sq-ft NJ facility produces groundbreaking gene therapy for NMIBC, marking $1B+ investment in innovative oncology treatment.
New 12,000-Sq-Ft Plant to Produce FDA-Approved Bladder Cancer Treatment ADSTILADRIN
Key Highlights
✔ Location: Parsippany, New Jersey (US headquarters)
✔ Investment: $500M+ in manufacturing (part of $1B+ total R&D spend)
✔ Product Focus: ADSTILADRIN – First FDA-approved bladder-targeted gene therapy
✔ Capacity: Dedicated production for high-risk non-muscle-invasive bladder cancer (NMIBC)
Strategic Significance
1. Breakthrough Therapy Production
- ADSTILADRIN is a non-replicating adenoviral vector therapy
- Single-dose treatment delivered via catheter directly to bladder
- Clinical benefits: 51% complete response rate in CIS+Ta/T1 patients (Phase 3 trial)
2. Manufacturing Excellence
🧪 Advanced Bioprocessing:
- Cell culture, viral vector production, purification
- Strict FDA cGMP compliance
📦 Supply Chain Control:
- End-to-end production under one roof
- Ensures therapy accessibility for US patients
3. Economic & Medical Impact
💊 Addresses Unmet Need:
- ~80,000 NMIBC cases annually in US
- Alternative to repeat BCG immunotherapy failures
💼 New Jersey Biotech Boost:
- Strengthens state’s “Medicine Chest of the World” status
- Creates high-skilled biopharma jobs
Leadership Perspectives
Brent Ragans, US President, Ferring:
“This facility embodies our commitment to transformative gene therapies. ADSTILADRIN offers new hope for bladder cancer patients who’ve exhausted other options.”
Jean-Frédéric Paulsen, Chairman:
*”A decade and $1B investment culminates today. We’re proud to deliver this first-of-its-kind treatment from our NJ home.”*
Fran (Patient Advocate):
“As someone who battled NMIBC, I know how desperately this therapy is needed. Today gives patients like me real hope.”
Technical Specifications
🏭 Facility Size: 12,000 sq ft
🔬 Cleanrooms: BSL-2 compliant
📅 Development Timeline: 10+ years from discovery to FDA approval (2022)
Market Context
💰 ADSTILADRIN Pricing: ~$157,000 per dose
🌎 Global Expansion Plans: EMA approval pending
🔍 Pipeline Potential: Platform for additional gene therapies
Ceremony Attendees
- Government:
- Rep. Mikie Sherrill’s office
- NJ State Sen. Joe Pennacchio
- Parsippany Mayor James Barberio
- Industry:
- Ferring’s global tech ops leadership
- Patient Advocates:
- Bladder Cancer Advocacy Network